Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study - Concepedia

Concepedia

Publication | Open Access

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

DOI Full Paper Access

57

Citations

8

References

2021

Year

Graham Smith, W. Keith Henry, Daniel Podzamczer, Marı́a del Mar Masiá, Christopher Bettacchi, Keikawus Arastéh, Hans Jaeger, Marie-Aude Khuong-Josses, María Luisa Montes-Ramírez, Hans‐Jürgen Stellbrink,

Open Forum Infectious Diseases

Abstract

Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.Clinical Trials Registration. NCT02120352.

References

	Year	Citations

Page 1